Research Topics
Species | Markus BredelSummaryAffiliation: Stanford University Country: USA Publications
| Collaborators
|
Detail Information
Publications
High-resolution genome-wide mapping of genetic alterations in human glial brain tumorsMarkus Bredel
Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California 94305 5151, USA
Cancer Res 65:4088-96. 2005..Finally, five novel minimally deleted regions were identified in a subset of tumors, containing putative candidate tumor suppressor genes (TOPORS, FANCG, RAD51, TP53BP1, and BIK) that could have a role in gliomagenesis...- Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomasMarkus Bredel
Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, California 94305 5151, USA
Cancer Res 65:8679-89. 2005..This approach has extended existing knowledge about the organizational pattern of gene expression in human gliomas and identified potential novel targets for future therapeutic development... - DNA topoisomerase IIalpha and Her-2/neu gene dosages in pediatric malignant gliomasClaudia Bredel
Department of General Neurosurgery, Neurocenter, University of Freiburg, D 79106 Freiburg, Germany
Int J Oncol 26:1187-92. 2005..The observed intratumor genetic heterogeneity for TIIalpha in PMNBGs may have an impact on the relevance of TIIalpha as a biological constituent of outcome in these neoplasms... - Chemogenomics: an emerging strategy for rapid target and drug discoveryMarkus Bredel
Division of Oncology, Stanford University School of Medicine, 269 Campus Drive, CCSR-1110, Stanford, California 94305-5151, USA
Nat Rev Genet 5:262-75. 2004 - Genomics-based hypothesis generation: a novel approach to unravelling drug resistance in brain tumours?Markus Bredel
Department of General Neurosurgery at the Neurocenter, University of Freiburg, Germany
Lancet Oncol 5:89-100. 2004..Recent progress in high-throughput bioanalytical methods for genome-wide studies has made possible a novel research model of initial hypothesis generation followed by functional testing of the generated hypothesis... - Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomasMarkus Bredel
Division of Oncology, Center for Clinical Sciences Research, Institute for Computational and Mathematical Engineering, Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305 5151, USA
J Clin Oncol 24:274-87. 2006..Pre-existing and acquired drug resistance are major obstacles to the successful treatment of glioblastomas... - Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumorsDejan Juric
Division of Oncology, Center for Clinical Sciences Research, Stanford University School of Medicine, Stanford, CA, USA
Methods Mol Biol 377:187-202. 2007..We have evaluated this approach and confirmed its efficacy in the human glioma genome... - Amplification of whole tumor genomes and gene-by-gene mapping of genomic aberrations from limited sources of fresh-frozen and paraffin-embedded DNAMarkus Bredel
Division of Oncology, Clinical Sciences Research, Stanford University School of Medicine, 269 Campus Dr, CCSR-1105, Stanford, CA 94305-5151, USA
J Mol Diagn 7:171-82. 2005..Therefore, this amplification method should lend itself to high-throughput genetic analyses of limited sources of tumor, such as fine-needle biopsies, laser-microdissected tissue, and small paraffin-embedded specimens... - Brain-tumour drug resistance: the bare essentialsMarkus Bredel
Department of General Neurosurgery, Neurocenter, University of Freiburg, Freiburg, Germany
Lancet Oncol 3:397-406. 2002..Elucidation of the cellular mechanisms involved in resistance regulation is needed for future progress in efficient approaches to selective modulation of drug resistance in these lesions... - DNA topoisomerase IIalpha predicts progression-free and overall survival in pediatric malignant non-brainstem gliomasMarkus Bredel
Department of General Neurosurgery, Neurocenter, University of Freiburg, Freiburg, Germany
Int J Cancer 99:817-20. 2002.... - Predicting outcome and tailoring treatment in high-grade gliomasMarkus Bredel
Department of General Neurosurgery-Neurocenter, University of Freiburg, Germany
Lancet Oncol 4:269-70. 2003 - NFKBIA deletion in glioblastomasMarkus Bredel
Department of Neurosurgery, Neurocenter, University of Freiburg, Freiburg, Germany
N Engl J Med 364:627-37. 2011.... - CHD5 is a tumor suppressor at human 1p36Anindya Bagchi
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
Cell 128:459-75. 2007..We demonstrate that Chd5 functions as a tumor suppressor in vivo and implicate deletion of CHD5 in human cancer. Identification of this tumor suppressor provides new avenues for exploring innovative clinical interventions for cancer... - Expression of DNA topoisomerase IIalpha in oligodendrogliomaMarkus Bredel
Institute of Neurology, Department of Neurosurgery, University of Vienna, Wien, Austria
Anticancer Res 22:1301-4. 2002..The widely vaiying expression levels of Topo ha in oligodendroglioma suggest this enzyme could be used for targeted selection of patients for Topo flu-interfering chemotherapy... - Nomograms as clinicobiological predictors of survival in glioblastomaMarkus Bredel
Lancet Oncol 9:5-6. 2008 - Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypesPeter Birner
Institute of Clinical Pathology, University of Vienna, Austria
Brain Pathol 13:133-43. 2003..Our findings denote for the first time distinct angiogenic subtypes of human glioblastoma which may prove relevant for anti-angiogenic therapy approaches... - Use of gene signatures to improve risk estimation in cancerChiang-Ching Huang
JAMA 299:1605-6. 2008 - High expression of DNA topoisomerase IIalpha and Ki-67 antigen is associated with prolonged survival in glioblastoma patientsMarkus Bredel
Institute of Neurology, University of Vienna, AKH 4J, , POB 48, Austria
Eur J Cancer 38:1343-7. 2002..We conclude that high expression of TIIalpha and Ki-67 appears to be associated with a prolonged survival in our cohort of GB patients...